Treatment Information

Back

Melanoma treatment details. Immunotherapy.

University of Medical Sciences , Poznan , Poland.

Survival: monthsCountry:Poland
Toxiciy Grade:2City/State/Province:Poznan
Treatments:ImmunotherapyHospital:University of Medical Sciences
Drugs:Journal:Link
Date:May 2015

Description:

Patients:
This phase 2 study involved 77 advanced melanoma patients with an average age of 51.7 years; 48% were male.

Treatment:
Patients received immunotherapy with a melanoma vaccine called AGI-101H, which is composed of human allogeneic (not identical to the patient) cells that are meant to direct the immune system to attack cancer cells.

Toxicities:
The most severe toxicities were of grade 2 and included fever, sweating, and injection site reactions.

Results:
The median overall survival was 17.3 months.

Correspondence: Dr. Jacek Mackiewicz; email: [email protected]



Back